|
 |
 |
 |
 |
 |
 |
- Home
- Join or Change Subscription
- GSI Community
- For New Patients
- About GIST
- Pediatric GIST & Carney Triad
- Treatments
- Ask the Professional
- Learning Center
- Voices of GIST
- Educational Materials
- GIST Support Wiki
- Donate
 | |
 | |
Pazopanib
Pazopanib is an oral angiogenesis inhibitor targeting vascular endothelial growth factor receptor (VEGFR), platelet derived growth factor receptor (PDGFR), and KIT. GIST cancers are usually dependent on KIT signaling. VEGF and PDGF are growth factors critical to the development and growth of blood vessels-- a process known as angiogenesis. Angiogenesis plays a critical role in the growth and spread of many tumor types, with VEGF and PDGF overexpression linked to multiple cancers.
Pazopanib is under development by GlaxoSmithKline (GSK). It is being evaluated as a monotherapy, in combination with targeted therapies, and in combination with cytotoxic chemotherapy. For Pazopanib information at the website of GlaxoSmithKline Pharmaceuticals click here.
As of December 2008 the clinical trial for Pazopanib as a monotherapy for patients with for Soft Tissue Sarcomas was listed as open and recruiting patients. Link to the trial page at clinicaltrials.gov
In a press release following the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm, Sweden, GSK stated:
“In a Phase II study of 142 patients with relapsed or refractory soft tissue sarcomas (leiomyosarcomas, adipocytic STS, synovial sarcomas and other STS types), pazopanib demonstrated activity in all tumour types except adipocytic STS. Nearly half (46%) of patients with synovial sarcomas reached the primary endpoint of progression free survival (PFS) at 12 weeks. PFS at 12 weeks was also reached by 38% of patients with leiomyosarcomas, and 36% of patients with other STS types.”
